SpectraScience Announces United Kingdom NHS Technology Alert
SAN DIEGO, CA--(Marketwired - Mar 23, 2015) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that a Technology Alert has been issued by the National Institute of Health Research (NIHR) which serves as the liaison between industry and the clinicians of the National Health Service (NHS) and facilitates clinical evaluations of new products and technologies of interest to the NHS. Technology Alerts are issued to inform NHS hospitals when newly supported technologies are commercially available.
The report can be downloaded in its entirety by going to the following link: http://www.hsc.nihr.ac.uk/topics/wavstat4-optical-biopsy-system-for-colorectal-canc/.
The report is based on the evaluation of the WavSTAT®4 Optical Biopsy System at St. James University Hospital in Leeds, England, as part of a European trial.
The WavStat trial in the UK was conducted in collaboration with the Colorectal Therapies Healthcare Technology Co-operative (HTC) based at St. James. Dr. Venkat Subramanian is the principal investigator for the UK trial.
The NHS was recently voted as the world's best healthcare system based on quality access and efficiency. Providing NHS clinical validation of WavSTAT4 has enabled SpectraScience to enter into the National Institute for Health and Clinical Excellence (NICE) MedTech evaluation program.
"NICE offers guidance on use of Medical technology across the NHS," said Michael Oliver, SpectraScience's President and CEO. "With the successful implementation of the clinical evaluation in the UK, we can quickly establish both the clinical and economic value for the NHS. This is in line with our goal to provide products and technologies that improve patient outcomes while reducing cost."
Mr. Oliver added, "Our WavSTAT4 Optical Biopsy System plays an important role in providing a fast, safe, accurate and cost-effective way to differentiate benign and cancerous lesions in the colon with a 96% negative predictive value. We look forward to implementations in multiple UK sites soon."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
